New test could unlock Life-Extending drug for more women with ovarian cancer
Knowledge-focused
Terminated
This study aimed to see if a new laboratory test (called the RAD51 assay) could identify more women with recurrent ovarian cancer who would benefit from the drug olaparib. It focused on patients whose cancer had returned after initial treatment. The goal was to find a better way …
Phase: PHASE2 • Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:30 UTC